Your browser is no longer supported. Please, upgrade your browser.
Settings
SONN [NASD]
Sonnet BioTherapeutics Holdings, Inc.
Index- P/E- EPS (ttm)-8.87 Insider Own0.10% Shs Outstand18.33M Perf Week-17.99%
Market Cap28.41M Forward P/E- EPS next Y-1.27 Insider Trans0.00% Shs Float16.48M Perf Month-27.23%
Income-68.50M PEG- EPS next Q- Inst Own2.70% Short Float2.04% Perf Quarter-50.32%
Sales5.70M P/S4.98 EPS this Y89.10% Inst Trans0.20% Short Ratio0.27 Perf Half Y-38.98%
Book/sh-0.14 P/B- EPS next Y-14.40% ROA-592.40% Target Price- Perf Year-67.16%
Cash/sh0.13 P/C12.35 EPS next 5Y- ROE- 52W Range1.52 - 7.89 Perf YTD-30.49%
Dividend- P/FCF- EPS past 5Y45.70% ROI- 52W High-80.35% Beta0.68
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin4.50% 52W Low1.97% ATR0.18
Employees9 Current Ratio0.50 Sales Q/Q- Oper. Margin- RSI (14)30.71 Volatility9.33% 9.09%
OptionableNo Debt/Eq- EPS Q/Q99.50% Profit Margin- Rel Volume0.81 Prev Close1.58
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.26M Price1.55
Recom2.00 SMA20-22.54% SMA50-29.18% SMA200-39.38% Volume1,022,512 Change-1.90%
May-10-21 06:30AM  
May-03-21 06:00AM  
Mar-29-21 04:30PM  
Mar-22-21 07:00AM  
Feb-16-21 08:10AM  
Feb-03-21 06:30AM  
Feb-01-21 06:30AM  
Jan-25-21 06:30AM  
Dec-17-20 06:30AM  
Nov-30-20 08:30AM  
Sep-01-20 08:30AM  
Aug-25-20 07:30AM  
Aug-24-20 07:37AM  
Aug-14-20 07:30AM  
Aug-04-20 07:35AM  
07:30AM  
Jul-20-20 07:30AM  
Jul-15-20 07:30AM  
May-18-20 07:30AM  
Apr-06-20 07:30AM  
Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.